Form 4: Masimo CEO Catherine Szyman Reports Stock Option and RSU Grants

Catherine M. Szyman, CEO of Masimo Corp, reports the acquisition of stock options and restricted stock units (RSUs) in a recent Form 4 filing.

Summary

• Catherine M. Szyman, CEO of Masimo Corporation, filed a Form 4 with the SEC.
• The filing reports the grant of non-qualified stock options and restricted stock units (RSUs) on March 11, 2025.
• The stock options grant covers 18,617 shares with an exercise price of $166.52.
• These options vest over a five-year period, with 20% vesting annually.
• The RSU award covers 8,407 units, each representing one share of Masimo common stock upon vesting.
• The RSUs vest ratably over four years, with 25% vesting annually.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of equity compensation is a standard practice and generally viewed favorably as it aligns management's interests with shareholders. There are no explicitly negative aspects in the filing.

Positives

• The grant of stock options and RSUs aligns the CEO's interests with those of the shareholders, incentivizing long-term value creation.
• The vesting schedules encourage continued service and commitment from the CEO over the next four to five years.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the options and RSUs.

Industry Context

Equity compensation is a common practice in the technology and medical device industries to attract, retain, and incentivize top executive talent. The specific terms of the grants (vesting schedule, exercise price) are generally benchmarked against peer companies.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in publicly traded companies, particularly in the tech and medical device sectors like Masimo.
• Vesting schedules of 4-5 years are typical to ensure long-term alignment with company performance.
• Companies like Medtronic, Stryker, and Boston Scientific also utilize similar equity compensation packages for their executives.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize the CEO to drive long-term value.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates